Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lun Luo

Showing results (191-200 of 214) with videos related to

Pageof 22
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|January 3, 2024
Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomyTsung Yu Yu, Hung Jen Wang, Min Tse Sung, et al.
Environmental Science & Technology|May 2, 2024
Soil's Hidden Power: The Stable Soil Organic Carbon Pool Controls the Burden of Persistent Organic Pollutants in Background SoilsLu Jiang, Jitao Lv, Kevin C Jones, et al.
Oncotarget|May 19, 2016
Mesenchymal stem cells promote pancreatic adenocarcinoma cells invasion by transforming growth factor-β1 induced epithelial-mesenchymal transitionHai-Sen Zhou, Xiao-Fang Su, Xing-Li Fu, et al.
Cells|April 1, 2020
Galectin-1 Overexpression Activates the FAK/PI3K/AKT/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and SurvivalYu-Li Su, Hao-Lun Luo, Chun-Chieh Huang, et al.
Frontiers in Oncology|December 19, 2022
The lowest level of tumor involvement is a significant prognostic factor for upper tract urothelial carcinoma after radical nephroureterectomy: A large retrospective cohort studyYing-Che Huang, Hung-Jen Wang, Min-Tse Sung, et al.
Cancer Genomics & Proteomics|March 2, 2026
ATIC Knockdown Reduces B7-H3 Expression and Oncogenic Signaling in Upper Tract Urothelial Carcinoma CellsHung-Lung Ke, Wei-Chi Hsu, Yin-Lun Chang, et al.
Frontiers in Oncology|December 17, 2020
Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World PracticeMing-Chun Kuo, Po-Jung Su, Chun-Chieh Huang, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 27, 2020
Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan-Japan UTUC Collaboration CohortHao Lun Luo, Chikara Ohyama, Shingo Hatakeyama, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 19, 2022
First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter AnalysisChang-Ting Lin, Po-Jung Su, Shih-Yu Huang, et al.
American Journal of Cancer Research|December 11, 2024
Recurrence risk of erythropoiesis-stimulating agents on early-stage urothelial carcinoma in patients with end stage renal diseaseHui-Ying Liu, Hao Lun Luo, Wen-Chin Lee, et al.
Pageof 22

Showing results (191-200 of 214) with videos related to

Sort By:
Pageof 22
International Journal of Urology : Official Journal of the Japanese Urological Association|January 3, 2024
Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomyTsung Yu Yu, Hung Jen Wang, Min Tse Sung, et al.
Environmental Science & Technology|May 2, 2024
Soil's Hidden Power: The Stable Soil Organic Carbon Pool Controls the Burden of Persistent Organic Pollutants in Background SoilsLu Jiang, Jitao Lv, Kevin C Jones, et al.
Oncotarget|May 19, 2016
Mesenchymal stem cells promote pancreatic adenocarcinoma cells invasion by transforming growth factor-β1 induced epithelial-mesenchymal transitionHai-Sen Zhou, Xiao-Fang Su, Xing-Li Fu, et al.
Cells|April 1, 2020
Galectin-1 Overexpression Activates the FAK/PI3K/AKT/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and SurvivalYu-Li Su, Hao-Lun Luo, Chun-Chieh Huang, et al.
Frontiers in Oncology|December 19, 2022
The lowest level of tumor involvement is a significant prognostic factor for upper tract urothelial carcinoma after radical nephroureterectomy: A large retrospective cohort studyYing-Che Huang, Hung-Jen Wang, Min-Tse Sung, et al.
Cancer Genomics & Proteomics|March 2, 2026
ATIC Knockdown Reduces B7-H3 Expression and Oncogenic Signaling in Upper Tract Urothelial Carcinoma CellsHung-Lung Ke, Wei-Chi Hsu, Yin-Lun Chang, et al.
Frontiers in Oncology|December 17, 2020
Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World PracticeMing-Chun Kuo, Po-Jung Su, Chun-Chieh Huang, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 27, 2020
Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan-Japan UTUC Collaboration CohortHao Lun Luo, Chikara Ohyama, Shingo Hatakeyama, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 19, 2022
First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter AnalysisChang-Ting Lin, Po-Jung Su, Shih-Yu Huang, et al.
American Journal of Cancer Research|December 11, 2024
Recurrence risk of erythropoiesis-stimulating agents on early-stage urothelial carcinoma in patients with end stage renal diseaseHui-Ying Liu, Hao Lun Luo, Wen-Chin Lee, et al.
Pageof 22